245 related articles for article (PubMed ID: 31007877)
1. Government pharmaceutical pricing strategies in the Asia-Pacific region: an overview.
Verghese NR; Barrenetxea J; Bhargava Y; Agrawal S; Finkelstein EA
J Mark Access Health Policy; 2019; 7(1):1601060. PubMed ID: 31007877
[No Abstract] [Full Text] [Related]
2. Overview of external reference pricing systems in Europe.
Rémuzat C; Urbinati D; Mzoughi O; El Hammi E; Belgaied W; Toumi M
J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123181
[TBL] [Abstract][Full Text] [Related]
3. External Reference Pricing for Pharmaceuticals-A Survey and Literature Review to Describe Best Practices for Countries With Expanding Healthcare Coverage.
Holtorf AP; Gialama F; Wijaya KE; Kaló Z
Value Health Reg Issues; 2019 Sep; 19():122-131. PubMed ID: 31416014
[TBL] [Abstract][Full Text] [Related]
4. [Risk sharing methods in middle income countries].
Inotai A; Kaló Z
Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
[TBL] [Abstract][Full Text] [Related]
5. Pricing of in-patent pharmaceuticals in the Middle East and North Africa: Is external reference pricing implemented optimally?
Kanavos P; Kamphuis BW; Fontrier AM; Colville Parkin G; Saleh S; Akhras KS
Health Policy; 2020 Dec; 124(12):1297-1309. PubMed ID: 32962876
[TBL] [Abstract][Full Text] [Related]
6. Drug price transparency initiative: A scoping review.
Ahmad NS; Makmor-Bakry M; Hatah E
Res Social Adm Pharm; 2020 Oct; 16(10):1359-1369. PubMed ID: 31987771
[TBL] [Abstract][Full Text] [Related]
7. How does external reference pricing work in developing countries: evidence from Iran.
Babaie F; Motevalli MH; Mehralian G; Peiravian F; Yousefi N
Front Pharmacol; 2023; 14():1034229. PubMed ID: 37408767
[No Abstract] [Full Text] [Related]
8. Variations in external reference pricing implementation: does it matter for public policy?
Gill J; Fontrier AM; Kyriopoulos D; Kanavos P
Eur J Health Econ; 2019 Dec; 20(9):1375-1397. PubMed ID: 31444673
[TBL] [Abstract][Full Text] [Related]
9. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
[TBL] [Abstract][Full Text] [Related]
10. European healthcare policies for controlling drug expenditure.
Ess SM; Schneeweiss S; Szucs TD
Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
[TBL] [Abstract][Full Text] [Related]
11. Does external reference pricing deliver what it promises? Evidence on its impact at national level.
Kanavos P; Fontrier AM; Gill J; Efthymiadou O
Eur J Health Econ; 2020 Feb; 21(1):129-151. PubMed ID: 31583483
[TBL] [Abstract][Full Text] [Related]
12. The End of the International Reference Pricing System?
Persson U; Jönsson B
Appl Health Econ Health Policy; 2016 Feb; 14(1):1-8. PubMed ID: 26112982
[TBL] [Abstract][Full Text] [Related]
13. Issues in drug pricing, reimbursement, and access in China with references to other Asia-Pacific region.
Chen Y; Schweitzer SO
Value Health; 2008 Mar; 11 Suppl 1():S124-9. PubMed ID: 18387056
[TBL] [Abstract][Full Text] [Related]
14. Transparency in pricing arrangements for medicines listed on the Australian Pharmaceutical Benefits Scheme.
Robertson J; Walkom EJ; Henry DA
Aust Health Rev; 2009 May; 33(2):192-9. PubMed ID: 19563308
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of efficiency enhancement in Iran Health Insurance Organization: a policy brief for pharmaceutical cost containment.
Yousefi N; Polroudi Moghaddam M; Afsharmanesh G; Peiravian F
Int J Health Plann Manage; 2020 Nov; 35(6):1503-1511. PubMed ID: 32901994
[TBL] [Abstract][Full Text] [Related]
16. Differences in external price referencing in Europe: a descriptive overview.
Leopold C; Vogler S; Mantel-Teeuwisse AK; de Joncheere K; Leufkens HG; Laing R
Health Policy; 2012 Jan; 104(1):50-60. PubMed ID: 22014843
[TBL] [Abstract][Full Text] [Related]
17. Consistency of new drug pricing in Korea: Bridging variations among personnel in price negotiations.
Kwon HY; Kim J
Health Policy; 2020 Sep; 124(9):965-970. PubMed ID: 32660816
[TBL] [Abstract][Full Text] [Related]
18. Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation.
Stargardt T; Schreyögg J
Appl Health Econ Health Policy; 2006; 5(4):235-47. PubMed ID: 17249840
[TBL] [Abstract][Full Text] [Related]
19. Impacts of cost containment strategies on pharmaceutical expenditures of the National Health Insurance in Taiwan, 1996-2003.
Lee YC; Yang MC; Huang YT; Liu CH; Chen SB
Pharmacoeconomics; 2006; 24(9):891-902. PubMed ID: 16942123
[TBL] [Abstract][Full Text] [Related]
20. International impact of external reference pricing: should national policy-makers care?
Fontrier AM; Gill J; Kanavos P
Eur J Health Econ; 2019 Nov; 20(8):1147-1164. PubMed ID: 31289948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
